Rui Freitas

This study identifies the CD44-CD206 axis as a glycoimmune checkpoint that promotes immune exclusion in bladder tumours with immature O-glycosylation.

This study identifies CD276 as a glycosylation-dependent immune checkpoint in colorectal cancer that promotes aggressiveness and immune escape by altering T-cell activation and cytokine production.

This study identifies hypoxia and glucose deprivation as drivers of aggressiveness in bladder cancer through metabolic adaptation and altered glycosylation.